Premature Ovarian Insufficiency - diagnostic and therapeutic challenges
DOI:
https://doi.org/10.12775/QS.2023.09.02.008Keywords
premature ovarian insufficiency, premature ovarian insufficiency stem cells, hormone replacement therapy, infertility treatment, early diagnosis, egg donationAbstract
Introduction and purpose: Premature Ovarian Insufficiency (POI) is a rare but serious disease diagnosed in about 1% of women before the age of 40. It is characterized by hypoestrogenism and an increase in the level of the follicle-stimulating hormone, which is associated with menstrual disorders, pregnancy failures and a reduced quality of life. The main causes of POI include a genetic background and autoimmune abnormalities, as well as increasingly jatrogenic factors. Care for patients is focused on hormone replacement therapy and infertility treatment. The aim of this review is to discuss current treatment methods, the impact of early diagnosis and the prevention of premature ovarian insufficiency, which affects the ability to have one's own offspring. The article also describes new methods of infertility treatment that are under investigation.
Materials and methods: This literature review is based on articles published in the PubMed database from 2015 to 2022 using the following phrases: premature ovarian insufficiency, premature ovarian insufficiency stem cells
State of knowledge: The only way to treat infertility in women with POI is egg donation. Currently, research is being conducted to achieve early diagnosis, introduce new treatment methods and reduce the number of iatrogenic forms of POI.
Conclusion: The main problem for women diagnosed with POI is the difficulty or often impossibility of having their own children. Egg donation does not allow for the transfer of the patient's genetic material, and is also not available as a treatment option in some countries. For this reason, new methods for early diagnosis, treatment, and prevention of POI are being developed.
References
V. Wesevich, A. N. Kellen, i L. Pal, „Recent advances in understanding primary ovarian insufficiency”, F1000Res, t. 9, s. F1000 Faculty Rev-1101, wrz. 2020, doi: 10.12688/f1000research.26423.1.
B. Ishizuka, „Current Understanding of the Etiology, Symptomatology, and Treatment Options in Premature Ovarian Insufficiency (POI)”, Front Endocrinol (Lausanne), t. 12, s. 626924, luty 2021, doi: 10.3389/fendo.2021.626924.
E. Rudnicka i in., „Premature ovarian insufficiency – aetiopathology, epidemiology, and diagnostic evaluation”, Prz Menopauzalny, t. 17, nr 3, s. 105–108, wrz. 2018, doi: 10.5114/pm.2018.78550.
K. Jankowska, „Premature ovarian failure”, Prz Menopauzalny, t. 16, nr 2, s. 51–56, cze. 2017, doi: 10.5114/pm.2017.68592.
The ESHRE Guideline Group on POI i in., „ESHRE Guideline: management of women with premature ovarian insufficiency†”, Human Reproduction, t. 31, nr 5, s. 926–937, maj 2016, doi: 10.1093/humrep/dew027.
S. Torrealday, P. Kodaman, i L. Pal, „Premature Ovarian Insufficiency - an update on recent advances in understanding and management”, F1000Res, t. 6, s. 2069, lis. 2017, doi: 10.12688/f1000research.11948.1.
S. J. Chon, Z. Umair, i M.-S. Yoon, „Premature Ovarian Insufficiency: Past, Present, and Future”, Front Cell Dev Biol, t. 9, s. 672890, maj 2021, doi: 10.3389/fcell.2021.672890.
I. Lambrinoudaki i in., „Premature ovarian insufficiency: A toolkit for the primary care physician”, Maturitas, t. 147, s. 53–63, maj 2021, doi: 10.1016/j.maturitas.2020.11.004.
T. Sato, A. Kusuhara, Y. Kasahara, T. Haino, H. Kishi, i A. Okamoto, „Follicular development during hormone replacement therapy in patients with premature ovarian insufficiency”, Reproductive Medicine and Biology, t. 20, nr 2, s. 234, kwi. 2021, doi: 10.1002/rmb2.12375.
Y. Huang i in., „Metabolic profile of women with premature ovarian insufficiency compared with that of age-matched healthy controls”, Maturitas, t. 148, s. 33–39, cze. 2021, doi: 10.1016/j.maturitas.2021.04.003.
A. Netterlid i in., „Premature ovarian failure after childhood cancer and risk of metabolic syndrome: a cross-sectional analysis”, European Journal of Endocrinology, t. 185, nr 1, s. 67–75, lip. 2021, doi: 10.1530/EJE-20-1275.
S. Sun, H. Chen, X. Zheng, C. Ma, i R. Yue, „Analysis on the level of IL-6, IL-21, AMH in patients with auto-immunity premature ovarian failure and study of correlation”, Exp Ther Med, t. 16, nr 4, s. 3395–3398, paź. 2018, doi: 10.3892/etm.2018.6592.
B. Komorowska, „Autoimmune premature ovarian failure”, Prz Menopauzalny, t. 15, nr 4, s. 210–214, grudz. 2016, doi: 10.5114/pm.2016.65666.
F. Aj, „Premature ovarian insufficiency: Pathogenesis and management”, Journal of mid-life health, t. 6, nr 4, grudz. 2015, doi: 10.4103/0976-7800.172292.
X. Ma i in., „A case-control study of thallium exposure with the risk of premature ovarian insufficiency in women”, Archives of Environmental & Occupational Health, t. 77, nr 6, s. 468–477, lip. 2022, doi: 10.1080/19338244.2021.1931797.
M. Sen, A. Kurl, i A. Khosroshahi, „Pregnancy in patients with systemic lupus erythematosus after cyclophosphamide therapy”, Lupus, t. 30, nr 9, s. 1509–1514, sie. 2021, doi: 10.1177/09612033211021163.
X. Zong i in., „Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial”, JAMA Oncol, t. 8, nr 2, s. 252–258, luty 2022, doi: 10.1001/jamaoncol.2021.6214.
R. Rossetti, I. Ferrari, M. Bonomi, i L. Persani, „Genetics of primary ovarian insufficiency”, Clinical Genetics, t. 91, nr 2, s. 183–198, 2017, doi: 10.1111/cge.12921.
S. M. Nelson i R. A. Anderson, „Prediction of premature ovarian insufficiency: foolish fallacy or feasible foresight?”, Climacteric, t. 24, nr 5, s. 438–443, wrz. 2021, doi: 10.1080/13697137.2020.1868426.
A. S. Dawood, M. A. El-Sharawy, D. W. Nada, i M. F. El-Sheikh, „Premature ovarian failure of autoimmune etiology in 46XX patients: is there a hope?”, J Complement Integr Med, t. 15, nr 4, maj 2018, doi: 10.1515/jcim-2017-0072.
P. J. Hagerman i R. Hagerman, „Fragile X syndrome”, Current Biology, t. 31, nr 6, s. R273–R275, mar. 2021, doi: 10.1016/j.cub.2021.01.043.
A. Rouen i in., „Whole exome sequencing in a cohort of familial premature ovarian insufficiency cases reveals a broad array of pathogenic or likely pathogenic variants in 50% of families”, Fertility and Sterility, t. 117, nr 4, s. 843–853, kwi. 2022, doi: 10.1016/j.fertnstert.2021.12.023.
X. Jiao, H. Ke, Y. Qin, i Z.-J. Chen, „Molecular Genetics of Premature Ovarian Insufficiency”, Trends in Endocrinology & Metabolism, t. 29, nr 11, s. 795–807, lis. 2018, doi: 10.1016/j.tem.2018.07.002.
X. Wang i in., „Long noncoding RNA HCP5 participates in premature ovarian insufficiency by transcriptionally regulating MSH5 and DNA damage repair via YB1”, Nucleic Acids Res, t. 48, nr 8, s. 4480–4491, maj 2020, doi: 10.1093/nar/gkaa127.
W. Liu i in., „Epg5 deficiency leads to primary ovarian insufficiency due to WT1 accumulation in mouse granulosa cells”, Autophagy, t. 19, nr 2, s. 644–659, luty 2023, doi: 10.1080/15548627.2022.2094671.
Ayesha, V. Jha, i D. Goswami, „Premature Ovarian Failure: An Association with Autoimmune Diseases”, J Clin Diagn Res, t. 10, nr 10, s. QC10–QC12, paź. 2016, doi: 10.7860/JCDR/2016/22027.8671.
M. Kirshenbaum i R. Orvieto, „Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal”, J Assist Reprod Genet, t. 36, nr 11, s. 2207–2215, lis. 2019, doi: 10.1007/s10815-019-01572-0.
N. Suzuki i in., „Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency”, Human Reproduction, t. 30, nr 3, s. 608–615, mar. 2015, doi: 10.1093/humrep/deu353.
L. Chansel-Debordeaux i in., „Successful live birth after in vitro maturation treatment in a patient with autoimmune premature ovarian failure: a case report and review of the literature”, Gynecological Endocrinology, t. 37, nr 12, s. 1138–1142, grudz. 2021, doi: 10.1080/09513590.2021.1928065.
H.-F. Li, Q.-H. Shen, W.-J. Chen, W.-M. Chen, Z.-F. Feng, i L.-Y. Yu, „Efficacy of Traditional Chinese Medicine Tonifying Kidney (Bushen) and Activating Blood (Huoxue) Prescription for Premature Ovarian Insufficiency: A Systematic Review and Meta-Analysis”, Evid Based Complement Alternat Med, t. 2020, s. 1789304, kwi. 2020, doi: 10.1155/2020/1789304.
Y. Cao, Y. Chen, P. Wang, J. Lu, X. Han, i J. She, „Network pharmacology and experimental validation to explore the molecular mechanisms of Bushen Huoxue for the treatment of premature ovarian insufficiency”, Bioengineered, t. 12, nr 2, s. 10345–10362, grudz. 2021, doi: 10.1080/21655979.2021.1996317.
K. Ma i in., „The effect of Bushen Culuan Decoction on anovulatory infertile women among 6 different diseases: a study protocol for a randomized, double-blinded, positively controlled, adaptive multicenter clinical trial”, Trials, t. 23, s. 563, lip. 2022, doi: 10.1186/s13063-022-06289-7.
W. Xue, F. Xue, T. Jia, i A. Hao, „Research and experimental verification of the molecular mechanism of berberine in improving premature ovarian failure based on network pharmacology”, Bioengineered, t. 13, nr 4, s. 9885–9900, doi: 10.1080/21655979.2022.2062104.
L. Wang, J. Liu, G. Nie, Y. Li, i H. Yang, „Danggui Buxue Tang Rescues Folliculogenesis and Ovarian Cell Apoptosis in Rats with Premature Ovarian Insufficiency”, Evidence-based Complementary and Alternative Medicine : eCAM, t. 2021, 2021, doi: 10.1155/2021/6614302.
„Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011) | Journal of Clinical Oncology”. https://ascopubs.org/doi/10.1200/JCO.21.00068?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed (dostęp 19 styczeń 2023).
R. Kado i W. J. McCune, „Ovarian protection with gonadotropin-releasing hormone agonists during cyclophosphamide therapy in systemic lupus erythematosus”, Best Pract Res Clin Obstet Gynaecol, t. 64, s. 97–106, kwi. 2020, doi: 10.1016/j.bpobgyn.2019.10.008.
Y.-Y. Lei i W. Yeo, „The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies”, Expert Opinion on Drug Safety, t. 20, nr 10, s. 1163–1175, paź. 2021, doi: 10.1080/14740338.2021.1926980.
N. M. Abogresha, S. S. Mohammed, M. M. Hosny, H. Y. Abdallah, A. M. Gadallah, i S. M. Greish, „Diosmin Mitigates Cyclophosphamide Induced Premature Ovarian Insufficiency in Rat Model”, International Journal of Molecular Sciences, t. 22, nr 6, mar. 2021, doi: 10.3390/ijms22063044.
J. Na i G. J. Kim, „Recent trends in stem cell therapy for premature ovarian insufficiency and its therapeutic potential: a review”, Journal of Ovarian Research, t. 13, 2020, doi: 10.1186/s13048-020-00671-2.
J. Galipeau i L. Sensébé, „Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities”, Cell Stem Cell, t. 22, nr 6, s. 824–833, cze. 2018, doi: 10.1016/j.stem.2018.05.004.
M. Ulin i in., „Human Mesenchymal Stem Cell Therapy and Other Novel Treatment Approaches for Premature Ovarian Insufficiency”, Reprod Sci, t. 28, nr 6, s. 1688–1696, maj 2021, doi: 10.1007/s43032-021-00528-z.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Izabela Hawranik, Mikołaj Tomasik, Paweł Warzyszak, Róża Małek , Maria Milczek, Wojciech Żołyniak, Szymon Niski, Ziemowit Żaba, Aleksandra Lisowska, Mateusz Skrzypek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 610
Number of citations: 0
